CASE STUDY:
AbbVie

Realizing pathology’s data-driven future with Proscia’s Concentriq® for Research
**FAST FACTS: ABBVIE + PROSCIA AT A GLANCE**

**CLIENT PROFILE**
AbbVie is an American biopharmaceutical company with 30,000 employees and $33B in annual revenue.

**ENGAGEMENT SUMMARY**
Struggling to realize the full potential of its pathology data with an outdated software system, AbbVie engaged Proscia to implement Concentriq for Research. AbbVie can now better manage, analyze, and share its data to unlock new insights and accelerate data-driven discovery.

**IMPLEMENTATION TIMELINE**
4 months

**WHOLE SLIDE IMAGES UNDER MANAGEMENT**
50,000+

**DIGITAL PATHOLOGY ECOSYSTEM**
- Scanner: Leica Aperio AT2
- Digital pathology platform: Proscia’s Concentriq for Research
- Image analysis: Indica HALO
- Storage infrastructure: On-premises Dell EMC Isilon

**LAYING THE FOUNDATION FOR CUTTING EDGE SCIENCE**

Like many life sciences organizations, AbbVie has been on the forefront of digital pathology adoption in an effort to drive new breakthroughs and accelerate its pre-clinical research. Its team has generated massive volumes of pathology images and increasingly complex data at the heart of its research; however, this information was trapped in outdated software systems that not only made it difficult to leverage but also forced manual, inefficient processes into AbbVie’s workflows.

AbbVie recognized that its then-current approach to digital pathology was hampering scientific potential. To leverage its data to the fullest potential, AbbVie required a modern digital pathology platform that would streamline its workflow, improve collaboration, and integrate with the other components of its ecosystem. In doing so, this platform would provide the team with a strong foundation for scaling digital pathology across additional data, stakeholders, and applications in the quest to unlock new insights.

What follows is the story of how AbbVie unified its pathology operations to accelerate data-driven discovery with Proscia’s Concentriq for Research.
OPTIMIZING THE WHOLE SLIDE IMAGE JOURNEY

As a first step in the deployment, AbbVie needed to migrate its existing archive of tens of thousands of whole slide images onto Concentriq for Research. Proscia led this process, defining a data migration plan that prioritized ingesting images from active studies, then backfilling the rest of the archive, to get AbbVie up-and-running. In turn, AbbVie's IT team was saved from the time-consuming effort of manually moving images from the legacy system.

Beyond the initial migration process, the Proscia team set up an optimized intake framework, enabling AbbVie's program managers to easily route whole slide images and associated metadata to the right project and, subsequently, user group. This intuitive structure gives them control over roles and permissions while streamlining data entry, quality control, and image assignment so that they can quickly launch studies with minimal overhead.

AbbVie's program managers previously lacked a good means of standardizing image metadata fields, resulting in inconsistent file naming conventions. With Concentriq for Research, they can create configurable project templates with controlled vocabularies across any number of images to enforce data consistency.

For image assessment and annotation, AbbVie's researchers were impressed with how Concentriq for Research offers such a wide breadth of functionality in everything from image viewing to robust image annotation and image manipulation tool sets. From a performance standpoint, the platform enables faster image loading and better resolution than AbbVie's previous software solution, driving both increased efficiency and an improved user experience. Concentriq for Research also offers real-time and asynchronous collaboration along with in-app notifications, enabling researchers to seamlessly work together.

Additionally, Concentriq for Research integrates with AbbVie's existing hardware and software ecosystem, including its image analysis applications, to centralize pathology data. AbbVie's researchers can open HALO with selected images from Concentriq for Research, eliminating the need to duplicate images. This integration was critical, as it enables AbbVie to save on storage costs while easily managing growing volumes of images and associated metadata. Through this integration, researchers can now quickly locate image analysis results along with all of their other images and data using Concentriq for Research's global search capability.

With its robust functionality, configurability, and interoperability, Concentriq for Research quickly became the comprehensive platform for scaling pathology operations across AbbVie's pre-clinical research.
ACCELERATING DATA-DRIVEN RESEARCH AND DISCOVERY

With more than 50,000 whole-slide images totaling over 45 terabytes of data on Concentriq for Research, AbbVie's team now has a future-proof digital pathology platform for managing and scaling its studies, as well as easily ingesting the hundreds of new whole slide images it generates each month. In summary, Proscia's Concentriq for Research delivers the following benefits to AbbVie:

• Optimized image ingestion (intake) framework with control over growing teams
• Streamlined data entry, QC, and image assignment
• Increased standardization, consistency, and configurability
• Dependable, all-encompassing global search
• Transformed user experience with a more intuitive user interface
• Best-of-breed integration with image analysis applications, along with other solutions in the future

By optimizing its pathology operations on Concentriq for Research, AbbVie now has greater visibility into its data. In turn, it is now positioned to better incorporate pathology data into its pre-clinical research, drive faster decision making, and ultimately capitalize on pathology's data-driven future. It plans to roll out Concentriq for Research in additional sites across the U.S. to further realize this promise.

To learn more about how Concentriq for Research can unify your pathology operations, visit Proscia.com.